Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters
- 1 January 1993
- journal article
- other
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 25 (1) , 37-46
- https://doi.org/10.1007/bf00662399
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patientsBreast Cancer Research and Treatment, 1990
- Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatinBreast Cancer Research and Treatment, 1989
- Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomataEuropean Journal of Cancer and Clinical Oncology, 1989
- Gonadotropin-releasing hormone specific binding sites in uterine leiomyomataBiochemical and Biophysical Research Communications, 1988
- GnRH analogs stimulate phospholipase C activity in mammary tumor membranes: modulation by GTPMolecular and Cellular Endocrinology, 1987
- Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinomaBreast Cancer Research and Treatment, 1986
- Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cellsEuropean Journal of Cancer and Clinical Oncology, 1985
- LHRH-Agonist treatment in clinical and experimental human breast cancerJournal of Steroid Biochemistry, 1985
- Human placental receptors for luteinizing hormone releasing hormoneBiochemical and Biophysical Research Communications, 1981
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976